Nuformix PLC NXP002 Pilot Study in Lung and Liver Fibrosis (4039D)
January 31 2018 - 2:00AM
UK Regulatory
TIDMNFX
RNS Number : 4039D
Nuformix PLC
31 January 2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN
PART, DIRECTLY OR INDIRECTLY, TO UNITED STATES NEWS WIRE SERVICES
OR IN OR INTO, AUSTRALIA, CANADA, JAPAN, THE UNITED STATES OF
AMERICA OR SOUTH AFRICA OR ANY JURISDICTION WHERE IT IS UNLAWFUL TO
DISTRIBUTE THIS ANNOUNCEMENT.
31 January 2018
Nuformix Plc
("Nuformix" or "the Company")
Positive Results from NXP002 Pilot Study in Lung and Liver
Fibrosis
Nuformix, the pharmaceutical development company using cocrystal
technology to unlock the therapeutic potential of approved small
molecule drugs, announces a positive outcome following innovative
pilot studies in multiple fibrotic diseases for its NXP002
programme.
Summary
-- Positive indication of efficacy using cutting-edge human tissue disease models
-- Demonstration that NXP002 inhibits fibrosis in functional
human tissue via a dual-action, significantly addressing both
inflammation and fibrosis components responsible for disease
progression
-- Results show a profound effect in inhibiting established
human fibrotic disease, offering future benefits to a wide spectrum
of patients
-- Proven safety and tolerability offers significant advantages over competitor products
-- Rapidly growing markets already valued in multiple billions
Working in parallel with the University of Newcastle and
Fibrofind and their proprietary fibrosis research models, Nuformix
has completed pilot pre-clinical studies that further validate the
potential for its NXP002 programme in successfully and safely
treating fibrosis.
Fibrotic disease is typically associated with high patient
mortality, increasing prevalence and a lack of safe and effective
treatments. Using cutting-edge human tissue disease models, the
studies have focussed on the potential for NXP002 to halt
progression in established lung and liver fibrosis. The results
demonstrate that NXP002 strongly inhibits fibrosis in functional
human tissue via a dual-action, which significantly addresses both
the inflammation and fibrosis components responsible for fibrotic
disease progression.
Following success in these innovative pilot studies Nuformix has
commenced additional studies to further support progress to use in
patients, which will run in parallel to Nuformix's human
pharmacokinetic studies for NXP002.
Dr Dan Gooding, CEO, Nuformix plc, said: "Traditional
pre-clinical fibrosis models offer limited utility as they don't
recreate the disease in a genetically or physiologically relevant
way, meaning success doesn't always translate into patients. In
contrast, the studies conducted at Newcastle University and
Fibrofind put the Nuformix NXP002 programme as close to patient as
possible. The results show a profound effect in inhibiting
established fibrotic disease, importantly at exposure levels that
we know are well-tolerated in patients and levels which the team
are confident can consistently be delivered using Nuformix
proprietary drug forms.
"We can take great confidence from our pilot data, particularly
in lung fibrosis, where we are able to study living human disease
tissue. Our data demonstrates NXP002 is superior to recently
approved treatments, whilst also providing the additional benefit
of vastly increased tolerability in long-term use, which is not
currently possible.
"These results give us great confidence in what will happen when
NXP002 reaches patients and robustly support entry to patient
proof-of-concept studies immediately after completion of our
pharmacokinetic studies."
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014.
Enquiries:
Nuformix Plc +44 (0) 1223
Dan Gooding, CEO 423667
Beaufort Securities Limited
(Broker) +44 (0) 20
Jon Belliss 7382 8300
Gable Communications Limited
(Financial PR) +44 (0) 20
John Bick / Justine James 7193 7463
About Fibrosis
Fibrosis is a degenerative disease affecting most vital organs.
Healthy tissue becomes scarred and impaired, ultimately resulting
in organ failure. Fibrotic conditions (e.g. lung fibrosis) are
typified by high patient mortality and are globally recognized as a
major unmet medical need. Despite alarming growth rates, current
treatments are either non-existent or offer marginal clinical
benefits whilst causing side effects so severe that many patients
elect to stop treatment.
About NXP002
NXP002 targets a key mechanistic pathway shared by many forms of
fibrosis, meaning effective oral delivery of NXP002 could treat
multiple fibrotic diseases. Despite demonstrable promise in several
fibrotic conditions, poor oral efficacy of the currently marketed
drug form means it is unable to exploit its full anti-fibrotic
potential. NXP002's cocrystal drug form will enable consistent and
efficacious oral delivery, creating the potential to treat multiple
fibrotic conditions whilst removing severe treatment side effects.
NXP002 is an example of Nuformix's strategy to use an approved drug
with a strong safety profile in new indications. Recognised safety
and human precedence combine to reduce development risk and
increase speed to clinic versus traditional biotech models.
Nuformix plc
Nuformix is a pharmaceutical development company using cocrystal
technology to unlock the therapeutic potential of approved small
molecule drugs. Nuformix' risk-mitigated development strategy has
resulted in a pipeline of discoveries through which it has
developed and patented novel cocrystal forms of approved small
molecules.
Nuformix has created an IP portfolio containing a range of
granted patents covering cocrystal forms of five small molecule
drugs. Nuformix is targeting high-value unmet needs with its lead
programmes in oncology supportive care: NXP001 and fibrosis:
NXP002.
Nuformix was established in Cambridge in 2008 and has invested
into pharmaceutical cocrystal R&D, establishing world-class
capability and know-how in cocrystal discovery and development,
yielding multiple product opportunities and revenues from products
under development. Nuformix plc shares are traded on the London
Stock Exchange's Official List under the ticker: NFX.L.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RESDMGFMMGZGRZZ
(END) Dow Jones Newswires
January 31, 2018 02:00 ET (07:00 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Apr 2024 to May 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From May 2023 to May 2024